Emergencies on direct oral anticoagulants: Management, outcomes, and laboratory effects of prothrombin complex concentrate

BACKGROUND: In the initial absence of specific reversal agents for factor Xa inhibitors (FXa‐Is), prothrombin complex concentrate (PCC) as a hemostatic agent has been recommended by guidelines. Since 2017, idarucizumab has been registered for dabigatran reversal. Still, data on the clinical outcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Bavalia, Roisin, Abdoellakhan, Rahat, Brinkman, Herm Jan M., Brekelmans, Marjolein P. A., Hamulyák, Eva N., Zuurveld, Marleen, Hutten, Barbara A., Westerweel, Peter E., Olie, Renske H., ten Cate, Hugo, Kruip, Marieke, Middeldorp, Saskia, Meijer, Karina, Coppens, Michiel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Article: Thrombosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292661/
https://www.ncbi.nlm.nih.gov/pubmed/32548555
http://dx.doi.org/10.1002/rth2.12336

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292661/
https://www.ncbi.nlm.nih.gov/pubmed/32548555
http://dx.doi.org/10.1002/rth2.12336

Ejemplares similares